Industry Analysts Just Upgraded Their Autolus Therapeutics plc (NASDAQ:AUTL) Revenue Forecasts By 12%

Celebrations may be in order for Autolus Therapeutics plc (NASDAQ:AUTL) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The consensus estimated revenue numbers rose, with their view now clearly much more bullish on the company's business prospects.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Following the upgrade, the current consensus from Autolus Therapeutics' eight analysts is for revenues of US$36m in 2025 which - if met - would reflect a sizeable 251% increase on its sales over the past 12 months. Per-share losses are expected to creep up to US$0.91. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$32m and losses of US$0.94 per share in 2025. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a sizeable increase to their revenue forecasts while also reducing the estimated loss as the business grows towards breakeven.

Check out our latest analysis for Autolus Therapeutics

Despite these upgrades, the analysts have not made any major changes to their price target of US$10.10, implying that their latest estimates don't have a long term impact on what they think the stock is worth.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Autolus Therapeutics' past performance and to peers in the same industry. It's clear from the latest estimates that Autolus Therapeutics' rate of growth is expected to accelerate meaningfully, with the forecast 251% annualised revenue growth to the end of 2025 noticeably faster than its historical growth of 41% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 19% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Autolus Therapeutics to grow faster than the wider industry.

The Bottom Line

The most important thing here is that analysts reduced their loss per share estimates for this year, reflecting increased optimism around Autolus Therapeutics' prospects. Fortunately, analysts also upgraded their revenue estimates, and our data indicates sales are expected to perform better than the wider market. Seeing the dramatic upgrade to this year's forecasts, it might be time to take another look at Autolus Therapeutics.

Even so, the longer term trajectory of the business is much more important for the value creation of shareholders. We have estimates - from multiple Autolus Therapeutics analysts - going out to 2027, and you can see them free on our platform here.

Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are upgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.